1
|
Román M, Baraibar I, López I, Nadal E,
Rolfo C, Vicent S and Gil-Bazo I: KRAS oncogene in non-small cell
lung cancer: Clinical perspectives on the treatment of an old
target. Mol Cancer. 17:332018. View Article : Google Scholar : PubMed/NCBI
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
3
|
Soda M, Choi YL, Enomoto M, Takada S,
Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K,
Hatanaka H, et al: Identification of the transforming EML4-ALK
fusion gene in non-small-cell lung cancer. Nature. 448:561–566.
2007. View Article : Google Scholar : PubMed/NCBI
|
4
|
Peters BJM, Cramer-Vd Welle CM, Smit AAJ,
Schramel FMNH and van de Garde EMW; Santeon NSCLC Study Group, :
Trends in prescribing systemic treatment and overall survival for
non-small cell lung cancer stage IIIB/IV in the Netherlands:
2008–2012. Cancer Epidemiol. 51:1–6. 2017. View Article : Google Scholar : PubMed/NCBI
|
5
|
Martin P and Leighl NB: Review of the use
of pretest probability for molecular testing in non-small cell lung
cancer and overview of new mutations that may affect clinical
practice. Ther Adv Med Oncol. 9:405–414. 2017. View Article : Google Scholar : PubMed/NCBI
|
6
|
Dasari S and Tchounwou PB: Cisplatin in
cancer therapy: Molecular mechanisms of action. Eur J Pharmacol.
740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
|
7
|
Lan H, Lu H, Wang X and Jin H: MicroRNAs
as potential biomarkers in cancer: Opportunities and challenges.
Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
|
8
|
Berindan-Neagoe I, Monroig Pdel C,
Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer
diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014.
View Article : Google Scholar : PubMed/NCBI
|
9
|
Mathe A, Scott RJ and Avery-Kiejda KA:
miRNAs and other epigenetic changes as biomarkers in triple
negative breast cancer. Int J Mol Sci. 16:28347–28376. 2015.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Lu J, Zhan Y, Feng J, Luo J and Fan S:
MicroRNAs associated with therapy of non-small cell lung cancer.
Int J Biol Sci. 14:390–397. 2018. View Article : Google Scholar : PubMed/NCBI
|
11
|
Hiew MSY, Cheng HP, Huang CJ, Chong KY,
Cheong SK, Choo KB and Kamarul T: Incomplete cellular reprogramming
of colorectal cancer cells elicits an epithelial/mesenchymal hybrid
phenotype. J Biomed Sci. 25:572018. View Article : Google Scholar : PubMed/NCBI
|
12
|
Yerukala Sathipati S and Ho SY:
Identifying the miRNA signature associated with survival time in
patients with lung adenocarcinoma using miRNA expression profiles.
Sci Rep. 7:75072017. View Article : Google Scholar : PubMed/NCBI
|
13
|
Wang Y, Sun H, Zhang D, Fan D, Zhang Y,
Dong X, Liu S, Yang Z, Ni C, Li Y, et al: TP53INP1 inhibits
hypoxia-induced vasculogenic mimicry formation via the ROS/snail
signalling axis in breast cancer. J Cell Mol Med. 22:3475–3488.
2018. View Article : Google Scholar : PubMed/NCBI
|
14
|
Yu SJ, Yang L, Hong Q, Kuang XY, Di GH and
Shao ZM: MicroRNA-200a confers chemoresistance by antagonizing
TP53INP1 and YAP1 in human breast cancer. BMC Cancer. 18:742018.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Saadi H, Seillier M and Carrier A: The
stress protein TP53INP1 plays a tumor suppressive role by
regulating metabolic homeostasis. Biochimie. 118:44–50. 2015.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Liao D, Li T, Ye C, Zeng L, Li H, Pu X,
Ding C, He Z and Huang GL: miR-221 inhibits autophagy and targets
TP53INP1 in colorectal cancer cells. Exp Ther Med. 15:1712–1717.
2018.PubMed/NCBI
|
17
|
Jiang PH, Motoo Y, Garcia S, Iovanna JL,
Pébusque MJ and Sawabu N: Down-expression of tumor protein
p53-induced nuclear protein 1 in human gastric cancer. World J
Gastroenterol. 12:691–696. 2006. View Article : Google Scholar : PubMed/NCBI
|
18
|
Li Q, Han Y, Wang C, Shan S, Wang Y, Zhang
J and Ren T: MicroRNA-125b promotes tumor metastasis through
targeting tumor protein 53-induced nuclear protein 1 in patients
with non-small-cell lung cancer. Cancer Cell Int. 15:842015.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Qin J, Luo M, Qian H and Chen W:
Upregulated miR-182 increases drug resistance in cisplatin-treated
HCC cell by regulating TP53INP1. Gene. 538:342–347. 2014.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Luo Q, Gu S, Li Y and Zhang Z: Improving
the expression of TP53INP1 in A549 cells enhances the sensitivity
of cells to arsenic treatment. Wei Sheng Yan Jiu. 46:120–125.
2017.PubMed/NCBI
|
21
|
Lan D, Wang L, He R, Ma J, Bin Y, Chi X,
Chen G and Cai Z: Exogenous glutathione contributes to cisplatin
resistance in lung cancer A549 cells. Am J Transl Res.
10:1295–1309. 2018.PubMed/NCBI
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Sarin N, Engel F, Kalayda GV, Mannewitz M,
Cinatl J Jr, Rothweiler F, Michaelis M, Saafan H, Ritter CA, Jaehde
U and Frötschl R: Cisplatin resistance in non-small cell lung
cancer cells is associated with an abrogation of cisplatin-induced
G2/M cell cycle arrest. PLoS One. 12:e01810812017. View Article : Google Scholar : PubMed/NCBI
|
24
|
Hong S, Li X, Zhao Y, Yang Q and Kong B:
53BP1 inhibits the migration and regulates the chemotherapy
resistance of ovarian cancer cells. Oncol Lett. 15:9917–9922.
2018.PubMed/NCBI
|
25
|
Zhu Z: Miltirone-induced apoptosis in
cisplatin-resistant lung cancer cells through upregulation of p53
signaling pathways. Oncol Lett. 15:8841–8846. 2018.PubMed/NCBI
|
26
|
Qin Y, Zhou X, Huang C, Li L, Liu H, Liang
N, Chen Y, Ma D, Han Z, Xu X, et al: Lower miR-340 expression
predicts poor prognosis of non-small cell lung cancer and promotes
cell proliferation by targeting CDK4. Gene. 675:278–284. 2018.
View Article : Google Scholar : PubMed/NCBI
|
27
|
Campbell KJ and Tait SWG: Targeting BCL-2
regulated apoptosis in cancer. Open Biol. 8(pii): 1800022018.
View Article : Google Scholar : PubMed/NCBI
|
28
|
Zhang CM, Zhao J and Deng HY: MiR-155
promotes proliferation of human breast cancer MCF-7 cells through
targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci.
20:792013. View Article : Google Scholar : PubMed/NCBI
|